Cancer susceptibility has been attributed to at least one heterozygous genetic alteration in a tumor suppressor gene (TSG) 1 . It has been hypothesized that subtle variations in TSG expression can promote cancer development 2,3 . However, this hypothesis has not yet been definitively supported in vivo. PTEN is a TSG frequently lost in human cancer and mutated in inherited cancer-predisposition syndromes 4 . Here we analyze Pten hypermorphic mice (Pten hy/+ ), expressing 80% normal levels of Pten. Pten hy/+ mice develop a spectrum of tumors, with breast tumors occurring at the highest penetrance. All breast tumors analyzed here retained two intact copies of Pten and maintained Pten levels above heterozygosity. Notably, subtle downregulation of Pten altered the steady-state biology of the mammary tissues and the expression profiles of genes involved in cancer cell proliferation. We present an alterative working model for cancer development in which subtle reductions in the dose of TSGs predispose to tumorigenesis in a tissue-specific manner.
Susceptibility to cancer has been historically attributed to inherited genetic alterations. Three decades ago, Alfred Knudson, a pioneer of cancer genetics, proposed a groundbreaking model for tumorigenesis, suggesting that cancer growth is initiated as a result of two genetic alterations of a single TSG 1, 5, 6 . Knudson envisioned tumor suppression as recessive characteristic, whereby an inactivating mutation present at birth is accompanied by a second somatic loss in the tumor. As a result of this visionary working model, a number of TSGs that undergo biallelic disruption or truncating point mutations were identified 1 .
In mouse models, monoallelic loss of major TSGs can be sufficient to trigger tumorigenesis in the absence of loss of heterozygosity (LOH), leading to a refinement of the Knudsonian hypothesis and the introduction of the concepts of haploinsufficiency and compound haploinsufficiency 5, [7] [8] [9] .
We and others have previously demonstrated that Pten (encoding the protein phosphatase and tensin homolog deleted on chromosome 10) is a bona fide haploinsufficient TSG [10] [11] [12] , whereas subsequent studies have shown that a further decrease of Pten dosage below heterozygosity leads to an accelerated progression to invasive cancer 2 .
With the advent of functional genomics, subtle changes in the expression levels of TSGs frequently detected in the general population have been proposed to dictate cancer susceptibility 3 . However, this hypothesis lacks conclusive experimental evidence.
Here we demonstrate through the generation and characterization of a Pten hy/+ mouse model that even a negligible decrease in Pten expression is sufficient to promote cancer susceptibility in mice.
To decrease the expression level of Pten below homozygosity, we targeted intron 3 of Pten with a neomycin (neo) cassette under the control of the cytomegalovirus (CMV) promoter, resulting in transcriptional interference (as reported in refs. 13 and 14; Supplementary  Fig. 1a) . Pten hy/+ mice were crossed with Pten +/− mice to generate hypomorphic mouse cohorts with decreasing levels of Pten expression (Pten wt > Pten hy/+ > Pten +/− > Pten hy/− ). To preserve a constant 129/C57BL/6 mixed genetic background, we crossed Pten hy/+ mice with Pten +/− mice for eight or more generations before analysis. As expected, Pten hy/+ mouse embryonic fibroblasts (MEFs) showed Pten levels below those of Pten wt and above those of Pten +/− mice (Supplementary Fig. 1b ; quantified in Supplementary Fig. 1c) . Analysis of Pten gene expression by quantitative RT-PCR in MEFs also showed a 20% reduction in mRNA levels in mice with Pten hy/+ cells (Supplementary Fig. 1d ).
We first evaluated the long-term survival and spontaneous tumor development of the Pten hypomorphic series of mice. Reduction of Pten dose in mice resulted in decreased survival (Fig. 1a-c) . Mean survival was 12 ± 1.8 months (mean ± s.d.) for Pten +/− mice and 8.5 ± 1.48 months for Pten hy/− mice. Unexpectedly, Pten hy/+ mice also showed a significant decrease in survival (Fig. 1a-c) . Similar to Pten +/− mutants 15 , Pten hy/+ mice had autoimmune disorders. Pten hy/+ mice developed lymphadenopathy and splenomegaly ( Supplementary  Fig. 2a-c) ; however, the onset of this autoimmune disease was delayed in the Pten hy/+ mice ( Supplementary Fig. 2a) , which explains the Subtle variations in Pten dose determine cancer susceptibility l e t t e r s difference in survival between the Pten +/− and Pten hy/+ populations. Similar to that for Pten +/− mice 15 , the histology of the spleen and lymph node from Pten hy/+ mice showed autoimmune lymphadenopathy ( Supplementary Fig. 2d ) and multiorgan inflammatory infiltration (Supplementary Fig. 2e ). Comparable with Pten +/− mice 15 , Pten hy/+ males developed a less severe autoimmune disorder, which explains their difference in survival as compared to female Pten hy/+ mice (compare Fig. 1b and 1c) .
Notably, Pten hy/+ mutant mice showed increased susceptibility to developing cancer. In particular, Pten hy/+ females had increased susceptibility to epithelial cancers ( Table 1 ) and had later onset of cancer than Pten +/− females (Fig. 1d) . Of note, 67% of Pten hy/+ females after the age of 14 months developed mammary carcinomas and 28% had endometrial atypical complex hyperplasia ( Table 1 and Supplementary Fig. 3a) , which is normally considered a precursor of endometrial tumors. Tumor size and proliferation increased with the reduction of Pten dosage (Fig. 1e) . Both male and female Pten hy/+ mice also developed multifocal primary lung carcinoma and intestinal polyps at low penetrance and with comparable incidence and onset ( Table 1 and Supplementary Fig. 3b) . Additionally, pathological analysis of the Pten hy/+ mammary tumors showed features of differentiated invasive ductal carcinoma, whereas Pten +/− tumors were less differentiated, with a prominent stromal component (Fig. 1e,  top) . Immunohistochemical analysis (Fig. 1f) , as well as protein blot detection of Pten (Fig. 1g) , confirmed that both Pten hy/+ and Pten +/− tumors retained Pten protein expression according to their genotype, and increased activation of the Akt protein (as indicated by phosphorylation at Ser473) as the levels of Pten were reduced, strongly suggesting that these tumors do not arise from subpopulations of cells expressing lower levels of the TSG. Furthermore, the slight upregulation of phosphorylated Akt (pAkt) in the Pten hy/+ mice indirectly suggested that Pten in these tumors is functionally active and lacks mutation or loss of heterozygosity (LOH), which was confirmed by mutational analysis (0/4 tumors showed mutations in any of the 9 exons of Pten) and LOH analysis by DNA blot (Supplementary Fig. 4) . In sum, these data demonstrate that after a long latency, Pten hy/+ mice develop mammary tumors at a high frequency and in the absence of a detectable Pten mutation or LOH. Although methylation may occur in a subset of tumors, that is unlikely to be the case in our model, given the high level of Pten protein expression as detected by protein blot and immunohistochemistry in the Pten hy/+ tumors.
We next checked whether a subtle decrease of Pten dose had a functional and cell-autonomous consequence in preneoplastic mammary tissue. First, we analyzed the proliferative index in preneoplastic mammary tissues from 2-month-old virgin control and Pten hy/+ female mice, and we observed increased Ki-67 staining in Pten hy/+ mammary glands (Fig. 2a) . Notably, liver, small intestine, pancreas, (Fig. 2a, bottom) . Next, we analyzed the level of Pten and phosphorylated Akt (pAkt-Ser473) in preneoplastic mammary glands and confirmed the retention of Pten expression (Supplementary Fig. 5a,b) , with slightly elevated pAkt levels (Supplementary Fig. 5a ).
Finally, we assessed in vitro whether survival and proliferative advantages of mammary epithelial cells (MMECs) from Pten hy/+ mice occurred in a cell-autonomous manner. The analysis of Pten wt and Pten hy/+ MMECs showed an enhanced proliferation of the Pten hy/+ MMECs (Fig. 2b) and an increased resistance to apoptosis after ultraviolet irradiation (Fig. 2c) . Protein blot analysis confirmed that Pten hy/+ MMECs had decreased levels of Pten and increased levels of pAkt and cyclin D1 (Fig. 2d) .
Notably, we validated our findings in MMECs from 3-month-old littermate mice of a pure C57BL/6 genetic background by short interfering (si) RNA-mediated Pten downregulation ( Supplementary  Fig. 6 ). Using this approach, we reduced Pten expression to ~80% that of the control cells. Analysis of proliferation confirmed that subtle reduction in Pten levels could promote hyperproliferation in C57BL/6 MMECs (Supplementary Fig. 6) .
Thus, our data show that a subtle decrease in the dose of Pten can affect cellular proliferation and suggest that the mouse mammary gland is the tissue most sensitive to this variation. The in vitro analysis also supports a cell-autonomous origin for mammary cancer phenotype. These findings are summarized in Figure 3 , where slight decreases in Pten levels in mammary tissue parallel the incidence of cancer observed in different tissues.
We then used gene expression profiling of Pten hy/+ MEFs to evaluate whether a subtle decrease in Pten would affect pathways involved in tumorigenesis. Genes passing the quality control filter were ranked by signal-to-noise ratio according to their differential expression using the Bioconductor RankProd package 16 . To identify relevant pathways or gene sets, ranked genes were analyzed according to gene set enrichment analysis (GSEA). We identified a significant upregulation (P < 0.01) of seven transcript gene sets, three of which are involved in cell-cycle regulation (Fig. 4a) . These include cell-cycle control and chromosomal-stability genes such as those encoding cyclin B2, cyclin D1, Mcm4 and Bub1. We validated these data in Pten hy/+ MMECs by quantitative RT-PCR (Fig. 4b and data not shown) . Stratification of Pten hy/+ upregulated genes (P < 0.01 as found by RankProd) according to classification by the Gene Ontology biological processes (GO-BP) database identified cell proliferation and M-phase regulation to be significantly (P < 0.01) upregulated in Pten hy/+ MEFs (see Fig. 4c for GO categories ordered by P value and fold enrichment factor of each GO compared to whole genome background in Pten hy/+ compared to Pten +/+ MEFs). Upregulation of these genes may contribute to the tumorigenesis induced by subtle decreases in Pten levels, as suggested by increased proliferation observed in the Pten hy/+ MMECs and mice. This analysis shows that subtle downregulation of Pten expression in MMECs drives the upregulation of genes encoding proteins involved in cellular proliferation, such as cyclin B2. Further, several transcripts associated with mitotic chromosomes are also upregulated, including the centromere proteins Cenpe and Bub1 and the cohesin-complex transcript Smc2l1, which promote chromosome segregation during the increased cycling in these cells (Fig. 4b) . Thus, a small decrease in Pten level can alter the gene expression profile of pathways essential for tumor formation and progression, thereby contributing to cancer susceptibility.
As PTEN is infrequently lost or mutated at the genomic level in individuals with breast cancer, despite a frequent decrease in the PTEN protein level 17, 18 , we checked whether a similar gene expression signature was also present in human breast tumors 19 . In a high percentage of invasive breast cancers (n = 40), PTEN expression was significantly l e t t e r s downregulated at the mRNA level (n = 7) (Supplementary Fig. 7a) . When compared to the average PTEN expression levels in normal mammary tissue, PTEN mRNA levels were greater than 65% of normal levels in 20% of the samples analyzed (Supplementary Fig. 7a,b) . Individuals found to have such subtle decreases in PTEN mRNA levels had protein levels that were similar to normal tissue (that is, stroma or normal breast epithelium) (Supplementary Fig. 7c ). In addition, all seven gene sets upregulated in our model were significantly enriched in patients with subtle decreases in PTEN (see Supplementary Fig. 7a for gene expression profiles and Supplementary Fig. 8 for each of the GSEA profiles), suggesting that this signature of enrichment is also present in human breast cancer biopsies (Supplementary Fig. 7a,b) .
Together, our data demonstrate that a subtle Pten reduction results in overt biological outcomes in the mammary epithelium, although, in vivo, non-cell autonomous effects may also contribute in view of the 'whole body' nature of this Pten mutant series. Notably, although reduction in PTEN dosage is strongly associated with human prostate cancer progression 2 , Pten hy/+ male mice did not develop prostate intraepithelial neoplasia. This may be due to the existence of a higher phosphatidylinositol-3-OH kinase (PI3K) signaling threshold, as it is likely specific tissues have differential sensitivity to the output of this signaling pathway, and to the requirement for additional genetic events in causing neoplasia in mice (for example, ETS family of transcription factors) 20 .
Our findings lead to a number of meaningful conclusions. We find that cancer can be promoted by the subtle reduction of a TSG without requiring an additional genetic hit at that locus. Although we cannot exclude additional genetic hits in other oncogenic and tumorsuppressive loci, we have proven the absence of Pten LOH or mutation in cancers arising in Pten hy/+ mice. It has been proposed that subtle variations in gene expression of a given TSG may promote cancer susceptibility 3 . However, to our knowledge, this is the first experimental evidence in support of that hypothesis to date. Furthermore, to our knowledge, it has never been reported that tumors initiated by a subtle downregulation of a TSG can progress in the absence of LOH of the wild type TSG allele 3 .
We here show in Pten hy/+ MEFs and preneoplastic tissues that a small reduction in Pten gene expression can trigger proliferation in direct association with the activation of a pro-proliferative signature. This suggests that epigenetic and environmental stresses leading to a subtle decrease in TSGs, without altering the architecture of the gene, may promote tumor-suppressor 'quasi-insufficiency' and increased susceptibility to cancer (Fig. 5a) .
On this basis, we propose a new model for TSG loss-driven tumorigenesis (Fig. 5b, left) . Our model revisits and further refines the classical saltatory model (that is, tumorigenesis through a stepwise genetic mutation-driven allelic loss; Fig. 5b, right) . We propose a continuum working model in which subtle variations in the expression of TSGs may have a profound impact on tumor susceptibility and progression. Hence, highly quantitative combinatorial methods for integrating genomic and proteomic information, along with high-throughput approaches for mutational analysis, will be Figure 5 Implications for tumorigenesis upon subtle reduction of TSG levels. (a) The 'no hits' model of cancer susceptibility. The rectangular green box represents a functional allele of a given TSG. The rectangular red box represents a nonfunctional allele inactivated by, for example, mutation or deletion. The rectangular green, yellow and red box represents an allele of a TSG whose expression is reduced below the normal levels. The black rectangle represents a genetic hit. Note that the model represented does not exclude the presence of additional hits on other loci. (b) A continuum model (left) for cancer initiation and promotion vis-à-vis a saltatory model (right). Note that in the continuum model, even subtle reductions in the dose of a TSG can initiate tumorigenesis in a tissue-specific manner. Phenotypes 1, 2 and 3 indicate that with the reduction of the TSG dose, the tumor phenotype can change in a tissue-specific manner, increasing incidence and aggressiveness of the disease. In the saltatory model, cancer arises from a stepwise genetic mutation-driven allelic loss.
required to precisely determine cancer susceptibility in any given tissue and to determine the detailed mechanisms of tumor progression; this work has critical implications in the development of both targeted and individualized approaches for cancer chemoprevention and therapy.
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